title: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
abstract: The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.
authors.affiliation: Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: J C
authors.initials: JC
authors.lastname: Yang
authors.forename: D J
authors.initials: DJ
authors.lastname: Schwartzentruber
authors.forename: P
authors.initials: P
authors.lastname: Hwu
authors.forename: F M
authors.initials: FM
authors.lastname: Marincola
authors.forename: S L
authors.initials: SL
authors.lastname: Topalian
authors.forename: N P
authors.initials: NP
authors.lastname: Restifo
authors.forename: M E
authors.initials: ME
authors.lastname: Dudley
authors.forename: S L
authors.initials: SL
authors.lastname: Schwarz
authors.forename: P J
authors.initials: PJ
authors.lastname: Spiess
authors.forename: J R
authors.initials: JR
authors.lastname: Wunderlich
authors.forename: M R
authors.initials: MR
authors.lastname: Parkhurst
authors.forename: Y
authors.initials: Y
authors.lastname: Kawakami
authors.forename: C A
authors.initials: CA
authors.lastname: Seipp
authors.forename: J H
authors.initials: JH
authors.lastname: Einhorn
authors.forename: D E
authors.initials: DE
authors.lastname: White
mesh_terms: D000328:Adult; D019496:Cancer Vaccines / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005260:Female; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D007114:Immunization; D007376:Interleukin-2 / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008545:Melanoma / Q000628:therapy*; D008562:Membrane Glycoproteins / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009842:Oligopeptides / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*; D058951:gp100 Melanoma Antigen
chemical_list: D019496:Cancer Vaccines; D015789:HLA-A2 Antigen; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D009842:Oligopeptides; C548637:PMEL protein, human; D010446:Peptide Fragments; D058951:gp100 Melanoma Antigen